Millennium Management
KROS icon

Millennium Management’s Keros Therapeutics KROS Stock Holding History

Millennium Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-90,000
Closed -$917K – 6117
2025
Q1 		$917K Buy
+90,000
New +$1.04M ﹤0.01% 4418
2024
Q3 		– Sell
-10,000
Closed -$457K – 6302
2024
Q2 		$457K Buy
+10,000
New +$537K ﹤0.01% 4646

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Millennium Management's KROS Position: Q1 2026 in Review

Millennium Management reduced its Keros Therapeutics (KROS) stake by 51% in Q1 2026, selling an estimated $1.75M and leaving 106,858 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #4271.

Millennium Management first reported a position in KROS in Q3 2020 and has held it in 21 quarters since. The position peaked at $33.3M in Q3 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Millennium Management held 106,858 shares of Keros Therapeutics worth $1.18M as of Q1 2026.
  • Millennium Management sold 113,351 Keros Therapeutics shares in Q1 2026, an estimated $1.75M.
  • Keros Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4271 holding.
  • Millennium Management first reported a position in Keros Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Millennium Management's Keros Therapeutics position peaked at $33.3M in Q3 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.